secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001104659-22-113551
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax appoints Richard J. Rodgers to board as independent director
--------------------------------------------------------------------

- Board size increased from 7 to 8; Rodgers appointed effective Oct 29, 2022 as Class I director until 2023 annual meeting.
- Rodgers has biopharma leadership background as co-founder/CFO of TESARO (acquired by GSK for >$5B) and CFO of Abraxis.
- Initial equity grant: options for 17,095 shares and 11,400 RSUs under 2015 Stock Incentive Plan.
- No committee assignments yet; affirmed independent with no material related-party transactions.
- Indemnification agreement entered into; press release issued Nov 1, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465922113551/0001104659-22-113551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465922113551/tm2229431d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-113551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer